Domenico De Berardis1, Michele Fornaro2, Laura Orsolini3, Felice Iasevoli4, Carmine Tomasetti4, Andrea de Bartolomeis4, Nicola Serroni5, Ida De Lauretis5, Gabriella Girinelli3, Monica Mazza6, Alessandro Valchera3, Alessandro Carano7, Federica Vellante1, Ilaria Matarazzo1, Giampaolo Perna8, Giovanni Martinotti5, Massimo Di Giannantonio5. 1. 1National Health Service,Department of Mental Health,Psychiatric Service of Diagnosis and Treatment,Hospital "G. Mazzini",Teramo,Italy. 2. 3New York Psychiatric Institute,Columbia University,New York,New York,USA. 3. 4Polyedra,Teramo,Italy. 4. 7Laboratory of Molecular Psychiatry and Psychopharmacotherapeutics,Section of Psychiatry,Department of Neuroscience,University School of Medicine "Federico II",Naples,Italy. 5. 2Department of Neurosciences and Imaging,Chair of Psychiatry,University "G. D'Annunzio",Chieti,Italy. 6. 8Department of Health Science,University of L'Aquila, L'Aquila,Italy. 7. 9National Health Service,Department of Mental Health,Psychiatric Service of Diagnosis and Treatment,Hospital "Madonna Del Soccorso",San Benedetto del Tronto,Ascoli Piceno,Italy. 8. 10Hermanas Hospitalarias,FoRiPsi,Department of Clinical Neurosciences,Villa San Benedetto Menni,Albese con Cassano,Como,Italy.
Abstract
OBJECTIVE: Agomelatine is a newer antidepressant but, to date, no studies have been carried out investigating its effects on C-reactive protein (CRP) levels in major depressive disorder (MDD) before and after treatment. The present study aimed (i) to investigate the effects of agomelatine treatment on CRP levels in a sample of patients with MDD and (ii) to investigate if CRP variations were correlated with clinical improvement in such patients. METHODS: 30 adult outpatients (12 males, 18 females) with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of MDD were recruited in "real-world," everyday clinical practice and treated with a flexible dose of agomelatine for 12 weeks. The Hamilton Rating Scale for Depression (HAM-D) and the Snaith-Hamilton Pleasure Scale (SHAPS) were used to evaluate depressive symptoms and anhedonia, respectively. Moreover, serum CRP was measured at baseline and after 12 weeks of treatment. RESULTS: Agomelatine was effective in the treatment of MDD, with a significant reduction in HAM-D and SHAPS scores from baseline to endpoint. CRP levels were reduced in the whole sample, with remitters showing a significant difference in CRP levels after 12 weeks of agomelatine. A multivariate stepwise linear regression analysis showed that higher CRP level variation was associated with higher baseline HAM-D scores, controlling for age, gender, smoking, BMI, and agomelatine dose. CONCLUSIONS: Agomelatine's antidepressant properties were associated with a reduction in circulating CRP levels in MDD patients who achieved remission after 12 weeks of treatment. Moreover, more prominent CRP level variation was associated with more severe depressive symptoms at baseline.
OBJECTIVE: Agomelatine is a newer antidepressant but, to date, no studies have been carried out investigating its effects on C-reactive protein (CRP) levels in major depressive disorder (MDD) before and after treatment. The present study aimed (i) to investigate the effects of agomelatine treatment on CRP levels in a sample of patients with MDD and (ii) to investigate if CRP variations were correlated with clinical improvement in such patients. METHODS: 30 adult outpatients (12 males, 18 females) with a Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnosis of MDD were recruited in "real-world," everyday clinical practice and treated with a flexible dose of agomelatine for 12 weeks. The Hamilton Rating Scale for Depression (HAM-D) and the Snaith-Hamilton Pleasure Scale (SHAPS) were used to evaluate depressive symptoms and anhedonia, respectively. Moreover, serum CRP was measured at baseline and after 12 weeks of treatment. RESULTS: Agomelatine was effective in the treatment of MDD, with a significant reduction in HAM-D and SHAPS scores from baseline to endpoint. CRP levels were reduced in the whole sample, with remitters showing a significant difference in CRP levels after 12 weeks of agomelatine. A multivariate stepwise linear regression analysis showed that higher CRP level variation was associated with higher baseline HAM-D scores, controlling for age, gender, smoking, BMI, and agomelatine dose. CONCLUSIONS: Agomelatine's antidepressant properties were associated with a reduction in circulating CRP levels in MDD patients who achieved remission after 12 weeks of treatment. Moreover, more prominent CRP level variation was associated with more severe depressive symptoms at baseline.
Authors: José M Castellano; Silvia Garcia-Rodriguez; Juan M Espinosa; María C Millan-Linares; Mirela Rada; Javier S Perona Journal: Biomolecules Date: 2019-11-01
Authors: Esmé Jansen van Vuren; Stephan F Steyn; Christiaan B Brink; Marisa Möller; Francois P Viljoen; Brian H Harvey Journal: Biomed Pharmacother Date: 2021-01-01 Impact factor: 6.529